Target
CD19
2 products, 1 indication
Indications
platinum-resistant high-grade serous ovarian cancer (2 products)
Loading...
1 drug
91 abstracts
Abstract
A pilot study of axicabtagene ciloleucel (axi-cel) for relapsed/refractory primary and secondary central nervous system lymphoma (PCNSL and SCNSL).Org: Dana-Farber Cancer Institute, DFCI/PCC Fellowship Program - Attendings, Massachusetts General Hospital, Kite Pharma, Division of Neuroradiology,
Abstract
Phase I study of CN201, a novel CD3xCD19 IgG4 bispecific antibody, in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia.Org: Institute of Hematology and Blood Disease Hospital, CAMS & PUMC, Tianjin, China, Henan Cancer Hospital, Zhengzhou, China, The Second Hospital of HeBei Medical University, Shijiazhuang, China, Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China, Institute of Hematology and Oncology, Harbin the First Hospital, Harbin, China,
Abstract
A potential best-in-class BCMA-CD19 bispecific CART with advanced safety by self-inhibiting IFNG signaling during CRS.Org: Celledit, The Third Affiliated Hospital of Southern Medical University, The First Affiliated Hospital of University of Science and Technology of China, The Second Xiangya Hospital of Central South University,
Abstract
Obecabtagene autoleucel (obe-cel, AUTO1) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL): Overall survival (OS), event-free survival (EFS) and the potential impact of chimeric antigen receptor (CAR)-T cell persistency and consolidative stem cell transplantation (SCT) in the open-label, single-arm FELIX phase Ib/II study.Org: Autolus Therapeutics, H. Lee Moffitt Cancer Center and Research Institute, The David and Etta Jonas Center for Cellular Therapy, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute,
Abstract
Safety and efficacy of armored huCART19-IL18 in patients with relapsed/refractory lymphomas that progressed after anti-CD19 CAR T cells.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Center for Cellular Immunotherapies, Department of Biostatistics, Epidemiology, and Informatics,
Abstract
Evolution of tisagenlecleucel use for the treatment of pediatric and young adult relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL): Center for International Blood & Marrow Transplant Research (CIBMTR) registry results.Org: Dana-Farber Cancer Institute, Boston Children's Hospital Cancer and Blood Disorders Center, Memorial Sloan Kettering Cancer Center, University of Colorado Denver, Children's Mercy Hospital,
Abstract
Combination therapy with the oncolytic virus CF33-CD19 and blinatumomab for the treatment of advanced solid tumors.Org: City of Hope National Comprehensive Cancer Center, Imugene,
Abstract
Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma.Org: Nutcracker Therapeutics, Emeryville, CA,
Abstract
Follow-up on phase 1 study of AT101, a novel anti-CD19 chimeric antigen receptor cell therapy (CAR-T) in patients with relapsed or refractory (r/r) b-cell non-Hodgkin lymphoma.Org: AbClon Inc., Ajou University Hospital, Donga University Hospital, Dong-A University Medical Center,
Abstract
Long term follow-up results of BRL-201 phase I study, a CRISPR-based non-viral PD-1 locus specific integrated anti-CD19 CAR-T cells in treating relapsed or refractory non-Hodgkin's lymphoma.Org: Brl Medicine Inc., Bone Marrow Transplantation Center,
Abstract
Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.Org: Department of Lymphoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital, Shijiazhuang, China, Shanghai East Hospital, Tongji University, Shanghai, China, Department of Hematology, Chinese PLA General Hospital, Beijing, China, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Department of Medical Oncology, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University, Guangzhou, China, The Fourth Hospital of Hebei Medical University, Tumor Hospital of Hebei Province, Shijiazhuang, China, The Fifth Medical Center of the General Hospital of the Chinese People's Liberation Army, Beijing, China, Department of Lymphoma, Peking University Cancer Hospital & Institute (Beijing Cancer Hospital), Beijing, China, Curon Biopharmaceutical, Shanghai, China,
Abstract
Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: CHU Rennes, Univ Rennes, Service d'hématologie clinique et thérapie cellulaire Hopital du Haut-Leveque CHU de Bordeaux, Medizinische Klinik und Poliklinik II, Universitätsklinikum Würzburg,
Abstract
Combination of pirtobrutinib and lentiviral transduced bispecific anti-CD20/CD19 (LV20.19) CAR T-cell therapy to improve outcomes in patients with relapsed/refractory lymphoma.Org: Medical College of Wisconsin Center for AIDS Intervention Research, Medical College of Wisconsin, Division of Hematology & Oncology,
Abstract
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.Org: Texas Oncology - Baylor Sammons Cancer Center, New South Wales Health,
Abstract
LOTIS-5: An ongoing, phase 3, randomized study of loncastuximab tesirine with rituximab (Lonca-R) versus immunochemotherapy in patients with R/R DLBCL.Org: Centrum Medyczne Pratia Poznań, Department of Oncology and Hematology, Humanitas University and IRCCS Humanitas Research Hospital, ADC Therapeutics SA, ADC Therapeutics Ltd., ADC Therapeutics America, Inc.,
Abstract
Patients (pts) with R/R large B-cell lymphoma (LBCL) treated with lisocabtagene maraleucel (liso-cel) nonconforming product (NCP) under the Expanded Access Protocol (EAP).Org: CCF Taussig Cancer Center,
Abstract
Outpatient blinatumomab with digital monitoring in patients with measurable residual disease positive (MRD+) B-ALL in a phase 4 study.Org: Comprehensive Cancer Center of Atrium Health Wake Forest Baptist, Adventist Health System/Sunbelt, Inc. d/b/a Advent Health Orlando, Current Health, Saint Francis Hospital, Inc.,
Abstract
Interim results from the ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.Org: Center for Blood Disorders and Cellular Therapy, Virginia Commonwealth University Massey Cancer Center,
Abstract
Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL).Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center,
Abstract
Secondary myeloid malignancy after CAR T cell therapy for non-Hodgkin lymphoma (NHL).Org: The Ohio State University, Division of Hematology, The Ohio State University, Department of Internal Medicine, The Ohio State University, College of Medicine,
Abstract
Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU) from the randomized, phase 3 TRANSFORM study.Org: University of Oklahoma Stephenson Cancer Center,
Abstract
Effect of CD22-directed CAR-T cells secreting anti-CD19 T cell engagers on control of leukemia progression compared to tandem anti-CD19/CD22 CAR-T cells.Org: Cancer Immunotherapy Unit (UNICA), Josep Carreras Leukaemia Research Institute, Department of Immunology, Ophthalmology and ENT, School of Medicine, Universidad Complutense,
Abstract
Lisocabtagene maraleucel (liso-cel) in patients (pt) with R/R mantle cell lymphoma (MCL): Subgroup analyses by number of prior systemic lines of therapy (LOT) and by response to prior Bruton tyrosine kinase inhibitor (BTKi) from the TRANSCEND NHL 001 MCL cohort (TRANSCEND-MCL).Org: Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Atrium Health, Levine Cancer Institute, Syneos Health,
Abstract
Impact of clinical response and AEs on health-related quality of life (HRQoL) in patients (pts) with R/R large B-cell lymphoma (LBCL): Pooled data from 4 lisocabtagene maraleucel (liso-cel) trials.Org: Massachusetts General Hospital Cancer Center, Harvard Medical School, Evidera PPD, Bethesda, Bristol Myers Squibb,
Abstract
Multicenter, randomized phase II study of epcoritamab for patients with large B-cell lymphomas achieving a partial response after CD19-directed CAR T-cell therapy (CAR-T).Org: Huntsman Cancer Institute/University of Utah, Washington University in St. Louis Department of Genetics, Division of Hematology, Mayo Clinic Florida,
Abstract
PMB-CT01 (BAFFR-CAR T cell) therapy to examine preliminary safety and clinical responses in patients with B-cell malignancies who are ineligible for or failed CD19-directed therapy, including CD19-negative disease.Org: City of Hope National Medical Center, PeproMene Bio,
Abstract
A study of a new mechanism: Intracellular retention allo-CART safety and efficacy for extranodal bulky B-NHL.Org: Fundamenta Therapeutics Co., Ltd., The First Affiliated Hospital of University of Science and Technology of China,
Abstract
Outcomes in patients (pts) with relapsed/refractory (R/R) diffuse large B cell lymphoma (DLBCL) treated with systemic therapy from real world experience (ORCHID) study.Org: Hematology Institute, Clinical Department of Hematology,
Abstract
Efficacy outcomes of treatments for double exposed chronic lymphocytic leukemia/small lymphocytic lymphoma: A systematic literature review.Org: Clinical and Administrative Pharmacy, Health Economics and Health Services Research,
Abstract
STRIvE-02 Arm C: Phase 1 study of concurrent PD-1 inhibition with B7-H3 CAR T cell immunotherapy for recurrent/refractory pediatric solid tumors.Org: Seattle Children’s Research Institute, Seattle Childrens Research Institute,
Abstract
A phase 1 dose escalation study of a novel coupled CAR T cell therapy, GCC19CART, for patients with metastatic colorectal cancer.Org: ICT, Innovative Cellular Therapeutics Co.,
Abstract
Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR).Org: University of Kentucky College of Medicine, Celgene, a Bristol Myers Squibb Company, Center for International Blood & Marrow Transplant Research, Medical College of Wisconsin,
Abstract
Quantitative systems pharmacology (QSP) model to predict combination activity of CD19-targeted antibody drug conjugate (loncastuximab tesirine) co-dosed with a CD20/CD3 T-cell bispecific (epcoritamab) in patients with diffuse large B-cell lymphoma (DLBCL).Org: Murray Hll, Metrum Research Group, Tariffville,
Abstract
CD19 expression in diffuse large b-cell lymphoma (DLBCL) patient biopsies after treatment with tafasitamab.Org: Incyte Research Institute,
Abstract
CD19/BCMA dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin lymphoma: An update.Org: Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Prevalence of adverse events following bispecific antibody therapy in non-Hodgkin lymphoma: A meta-analysis.Org: Division of Hematology/Oncology, Department of Medicine, University Of Toledo, Mayo Clinic, Mayo Clinic Arizona, Phoenix, AZ, Mayo Clinic Scottsdale,
Abstract
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM).Org: Gracell Biotechnologies Ltd,
Abstract
Safety and efficacy of obecabtagene autoleucel (obe-cel, AUTO1), a fast-off rate CD19 CAR, in relapsed/refractory adult B-cell acute lymphoblastic leukemia (r/r B-ALL): Top line results of the pivotal FELIX study.Org: University College London Cancer Institute, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, Manchester Royal Infirmary, Texas Transplant Physician Grp, PLLC,
Abstract
Outcomes following brexucabtagene autoleucel administered as an FDA-approved therapy for adults with relapsed/refractory B-ALL.Org: University of Chicago, H. Lee Moffitt Cancer Center and Research Institute, City of Hope National Medical Center, University of Washington/Fred Hutchinson Cancer Research Center, University of Colorado Cancer Center,
Abstract
Primary overall survival analysis of the phase 3 randomized ZUMA‑7 study of axicabtagene ciloleucel versus standard‑of‑care therapy in relapsed/refractory large B-cell lymphoma.Org: Vanderbilt University Cancer Center, University of Amsterdam, Stanford University School of Medicine, Washington University School of Medicine, Hematology Department, Institut Català d'Oncologia-Hospitalet,
Abstract
Real-world outcomes of brexucabtagene autoleucel (brexu-cel) for relapsed or refractory (R/R) mantle cell lymphoma (MCL): A CIBMTR subgroup analysis by prior treatment.Org: City of Hope National Medical Center, Center for International Blood and Marrow Transplant Research, University of North Carolina School of Medicine, Moffitt Cancer Center, Stanford University Hospital,
Abstract
Real-world outcomes with novel therapies in R/R DLBCL.Org: Dana-Farber Cancer Institute, Genmab US, Inc., AbbVie Inc., North Chicago, IL,
Abstract
Five-year follow-up update of defined-composition CD19 CAR T-cell therapy for relapsed/refractory CLL.Org: Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Seattle Gummy Company, Wave Life Sciences,
Abstract
Pediatric oncologist referral practices for CAR T-cell therapy: A mixed methods study.Org: Seattle Children's Hospital, University of Washington and Fred Hutchinson Cancer Research Centre, Seattle, WA, Seattle Children's Research Institute, Fred Hutchinson Cancer Center/Division of Hematology and Oncology,
Abstract
Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory (R/R) follicular lymphoma (FL).Org: Dana-Farber Cancer Institute, Gilead, Stanford University School of Medicine, City of Hope National Medical Center, The University of Kansas Medical Center,
Abstract
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma.Org: Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, Gracell Biotechnologies Ltd., Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Outpatient practice utilization for CAR-T and T cell engager in patients with lymphoma and multiple myeloma.Org: Mayo Clinic, Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ,
Abstract
Impact of age, prior therapies, and subsequent transplant on long-term outcomes of adults with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.Org: Moffitt Cancer Center, University of Washington & Fred Hutchinson Cancer Center, Memorial Sloan Kettering Cancer Center, CHU Rennes, Université Rennes,
Abstract
Outcomes among adult recipients of CD19 CAR T-cell therapy for Burkitt lymphoma.Org: Fred Hutchinson Cancer Research Center, Boston University Medical Center, Massachusetts General Hospital, Dana-Farber Cancer Institute, Medical College of Wisconsin,
Abstract
A phase 1 study of AT101, a novel anti-CD19 CAR-T cell therapy targeting a membrane-proximal epitope of CD19, in patients with relapsed or refractory B cell non-Hodgkin lymphoma.Org: Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, Ulsan University Hospital, Ulsan, South Korea,
Abstract
Effect of the killing style of individual CAR T cells on the clinicopathological behavior of therapeutic products in the clinic.Org: Center for Cell and Gene Therapy, Texas Children’s Hospital, Houston Methodist Hospital, Department of Pathology and Genomic Medicine, Baylor College of Medicine, University of Houston,
Abstract
GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale.Org: Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin, China, Blood Institute of the Chinese Academy of Medical Sciences, Tianjin, China, Department of Lymphoma, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, China, Anhui Medical University Second Affiliated Hospital, Anhui, China, School of Medicine, Tongji Hospital of Tongji University, Shanghai, China,
Abstract
High complete response rate with TNB-486 in relapsed/refractory follicular lymphoma: Interim results from an ongoing phase 1 study.Org: AstraZeneca, Ancora Biotech, Inc.,
Abstract
Phase 1 results with anti-CD19 allogeneic CAR T ALLO-501/501A in relapsed/refractory large B-cell lymphoma (r/r LBCL).Org: H. Lee Moffitt Cancer Center and Research Institute, University of Miami Sylvester Cancer Center, Ronald Reagan UCLA Medical Center, Mayo Clinic Comprehensive Cancer Center, Phoenix, AZ, Colorado Blood Cancer Institute and Sarah Cannon Research Institute,
Abstract
Phase 1b open-label study of loncastuximab tesirine in combination with other anticancer agents in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (LOTIS-7).Org: Blood and Marrow Transplant Group of Georgia, Virginia Cancer Specialists, ADC Therapeutics America, Inc., Institute of Hematology “Seràgnoli”, Oxford University Hospitals, NHS Trust,
Abstract
The ELiPSE-1 study: A phase 1, multicenter, open-label study of CNTY-101 in subjects with relapsed or refractory CD19-positive B-cell malignancies.Org: Center for Blood Disorders and Cellular Therapy, Swedish Cancer Institute, Swedish Cancer Institute, Century Therapeutics, University of Texas MD Anderson Cancer Center, Henry Ford Health System,
Abstract
AB-101, an allogeneic, non–genetically modified, natural killer (NK) cell therapy, evaluated as monotherapy or in combination with rituximab in R/R non-Hodgkin lymphoma.Org: Fox Chase Cancer Center, O’Neal Comprehensive Cancer Center at the University of Alabama at Birmingham School of Medicine, Norton Cancer Institute, Texas Oncology PA, OHSU - Oregon Health and Science University,
Abstract
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.Org: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China, Kunming, China, Chongqing Precision Biotech Co., Ltd., Chongqing, China,
Abstract
Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T).Org: Massachusetts General Hospital, Incyte, Medical College of Wisconsin, Oregon Health & Science University, Washington University School of Medicine in St. Louis,
Abstract
Subgroup analyses of primary refractory (refr) vs early relapsed (rel) large B-cell lymphoma (LBCL) from the TRANSFORM study of lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) as second-line (2L) therapy.Org: Celgene, a Bristol-Myers Squibb Company,
Abstract
Patient perspectives on CLL treatment side effects: A sub-analysis of the VOICE survey.Org: Alfred Health, H. Lee Moffitt Cancer Center and Research Institute, Antalya Research and Training Hospital, Fundaleu, University Hospital Hradec Králové,
Abstract
Effect of bispecific B7H3 x CD19 CAR T cells on host CD19 expression and CAR T cell engraftment.Org: University of Washington and Fred Hutchinson Cancer Research Centre, Seattle Children's Hospital, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, St. Jude Children's Research Hospital,
Abstract
Impact of fludarabine exposure on the depth and duration of lymphopenia and CAR T-cell outcomes.Org: Pediatric Oncology Branch, Clinical Center National Institutes of Health, Center for Cancer Research, National Cancer Institute, National Cancer Institute, Vilnius, Lithuania, Nihon Medi-Physics, Pharmacy Department,
Abstract
Crossing the US-Mexico border for cancer care: Which treatments are more sought-after?Org: Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, University of North Carolina at Chapel Hill, Vanderbilt University Medical Center, ISSSTE CMN 20 De Noviembre, Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico,
Abstract
Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Single center experience of using Anakinra prophylactically at Day 0 to reduce CD19 CART toxicities.Org: Augusta University Georgia Cancer Center, University of Illinois Urbana-Champaign, College of Medicine, University of the Philippines - Manila, Medical College of Georgia, Augusta, GA, Department of Internal Medicine C, University Hospital Greifswald, Greifswald, Germany,
Abstract
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).Org: Sarah Cannon Research Institute/Tennessee Oncology, Tennessee Oncology, PLLC, Dana-Farber Cancer Institute, MD Anderson Cancer Center, University of Lille,
Abstract
Quality assessment of information on chimeric antigen receptor T-cell therapy on YouTube: An analysis.Org: Government Medical College and Hospital, Chandigarh, India, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, University of Vermont Medical Center; Division of Hematology-Oncology, Burlington, VT, New York Presbyterian Queens, Flushing, NY, Institute of Liver and Biliary Sciences, Delhi, India,
Abstract
Hypophosphatemia and thrombocytopenia: A retrospective chart review to identify markers for prediction of CRS and ICANS in CAR T-cell therapy.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, University of Arizona, Tucson, AZ, University of Arizona Cancer Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital,
Abstract
Upgrading the non-gene-editing, allogeneic ThisCART platform for extending persistence in vivo.Org: Fundamenta Therapeutics Co.,Ltd., Suzhou, China, Soochow University, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China,
Abstract
A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
Real-world use of tisagenlecleucel in children and young adults with relapsed or refractory B-cell lymphomas.Org: Cincinnati Children's Hospital Medical Center, Department of Pediatrics & Adolescent Medicine, Queen Mary Hospital, Division of Pediatric Hematology-Oncology, Department of Pediatrics, Charles-Bruneau Cancer Center, CHU Sainte-Justine, Montreal, QC, Canada, Oncology and Bone Marrow Transplant, School of Medicine & Public Health,
Abstract
Subgroup analysis from a phase II trial of ponatinib and blinatumomab in relapsed/refractory (R/R) Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in lymphoid blast phase.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Houston, TX,
Abstract
Comprehensive myeloid-derived suppressor cell (MDSC) immunophenotyping and functional assessment in chimeric antigen receptor (CAR) T therapy.Org: Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC, Duke University Medical Center, Duke University Cancer Institute,
Abstract
ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.Org: Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, Dana-Farber Cancer Institute, Boston, MA, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, Hematology Department, Institut Català d'Oncologia-Hospitalet, Barcelona, Spain, University of Lille, Centre Hospitalier Universitaire, Lille, France,
Abstract
Early detection of CRS after CAR-T therapy using wearable monitoring devices: Preliminary results in relapsed/refractory multiple myeloma (RRMM).Org: Icahn School of Medicine at Mount Sinai/Tisch Cancer Institute, Current Health, Dorset County Hospital, NHS Foundation Trust, Tisch Cancer Institute, Mount Sinai School of Medicine,
Abstract
Immediate inpatient toxicities associated with CAR T-cell therapy: Real world data from a national inpatient sample.Org: Monmouth Medical Center, JJM Medical College, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ,
Abstract
Characterizing outcomes in severe cytopenias by 3 months in BCMA and CD19 CAR-T cell therapies: A single institution experience.Org: Department of Medicine, Icahn School of Medicine at Mount Sinai, Emory University School of Medicine, Biostatistics Shared Resource, Emory University, Atlanta, GA, USA, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, Winship Cancer Institute of Emory University, Atlanta, GA, Emory University, Atlanta, GA, Department of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, Department of Medicine, Massachusetts General Hospital, Boston, MA, Department of Medicine, Emory University School of Medicine, Atlanta, GA, Department of Urology, Emory University School of Medicine, Atlanta, GA,
Abstract
Rural communities and health professional shortage areas (HPSA) and access to immune effector cellular therapy and lymphoma/myeloma clinical trials.Org: The University of Kansas Medical Center, University of Kansas Medical Center, Department of Biostatistics & Data Science, The University of Kansas Cancer Center, US Myeloma Research Innovations Research Collaborative (USMIRC), University of Kansas Medical Center Department of Internal Medicine,
Abstract
Mini-hyper-CVD plus inotuzumab ozogamicin (InO), with or without blinatumomab (Blina), in older patients with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL): Updates from a phase II trial.Org: Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Outcomes with bendamustine lymphodepletion prior to brexucabtagene autoleucel for mantle cell lymphoma.Org: Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA,
Abstract
Adverse events during chimeric antigen receptor T-cell (CAR-T) therapy for hematologic malignancies (HM): Real-world, US patient experience.Org: EVERSANA, Burlington, ON, Canada, Milwaukee, Wigen Biomedicine Technology (Shanghai), Bangalore Medical College And Research Institute, Indiana University – Purdue University Indianapolis,
Abstract
Real-world duration of hospitalization for CAR-T treatment: U.S. patient experience in multiple hematologic malignancies.Org: EVERSANA, Burlington, ON, Canada, Milwaukee, Wigen Biomedicine Technology (Shanghai), Yardley, PainReform,
Abstract
Mini-hyper-CVD with venetoclax (Ven) for patients with relapsed/refractory (R/R) Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL): A phase II study.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX,
Abstract
A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan,
Abstract
Five-year subgroup analysis of tafasitamab + lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma.Org: Vall d’Hebron Institute of Oncology (VHIO), Ludwig-Maximilians-University Hospital, University of Eastern Piedmont, Institut Català D'Oncologia, IDIBELL,
Abstract
Racial disparities in DLBCL: Analysis of SEER data from 2010-2019.Org: Harvard T.H. Chan School of Public Health, Optum,
Abstract
CAR-T therapy access with Louisiana Medicaid: A single institution retrospective analysis.Org: LSU Health Shreveport, Feist-Weiller Cancer Center at LSUHSC-Shreveport, LSU-Shreveport, Louisiana State University (Shreveport) Program at Feist-Weiller Cancer Center, Shreveport, LA,
Drug
brenetafuspAbstract
Racial disparities and inequity in clinical trials of chimeric antigen receptor T-cell therapy.Org: Jacobi Medical Center/NYCHHC, Jacobi Medical Center/Albert Einstein College of Medicine, MedStar Union Memorial Hospital, Rochester Regional Hospital, Jacobi Medical Center/North Central Bronx,